TY - JOUR
T1 - Incorporating Pharmacometrics into Pharmacoeconomic Models
T2 - Applications from Drug Development
AU - Srinivasan, Meenakshi
AU - White, Annesha
AU - Chaturvedula, Ayyappa
AU - Vozmediano, Valvanera
AU - Schmidt, Stephan
AU - Plouffe, Leo
AU - Wingate, La’Marcus M.T.
N1 - Funding Information:
This work was supported from a grant from the Bill & Melinda Gates Foundation.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Pharmacometrics is the science of quantifying the relationship between the pharmacokinetics and pharmacodynamics of drugs in combination with disease models and trial information to aid in drug development and dosing optimization for clinical practice. Considering the variability in the dose–concentration–effect relationship of drugs, an opportunity exists in linking pharmacokinetic and pharmacodynamic model-based estimates with pharmacoeconomic models. This link may provide early estimates of the cost effectiveness of drug therapies, thus informing late-stage drug development, pricing, and reimbursement decisions. Published case studies have demonstrated how integrated pharmacokinetic–pharmacodynamic–pharmacoeconomic models can complement traditional pharmacoeconomic analyses by identifying the impact of specific patient sub-groups, dose, dosing schedules, and adherence on the cost effectiveness of drugs, thus providing a mechanistic basis to predict the economic value of new drugs. Greater collaboration between the pharmacoeconomics and pharmacometrics community can enable methodological improvements in pharmacokinetic–pharmacodynamic–pharmacoeconomic models to support drug development.
AB - Pharmacometrics is the science of quantifying the relationship between the pharmacokinetics and pharmacodynamics of drugs in combination with disease models and trial information to aid in drug development and dosing optimization for clinical practice. Considering the variability in the dose–concentration–effect relationship of drugs, an opportunity exists in linking pharmacokinetic and pharmacodynamic model-based estimates with pharmacoeconomic models. This link may provide early estimates of the cost effectiveness of drug therapies, thus informing late-stage drug development, pricing, and reimbursement decisions. Published case studies have demonstrated how integrated pharmacokinetic–pharmacodynamic–pharmacoeconomic models can complement traditional pharmacoeconomic analyses by identifying the impact of specific patient sub-groups, dose, dosing schedules, and adherence on the cost effectiveness of drugs, thus providing a mechanistic basis to predict the economic value of new drugs. Greater collaboration between the pharmacoeconomics and pharmacometrics community can enable methodological improvements in pharmacokinetic–pharmacodynamic–pharmacoeconomic models to support drug development.
UR - http://www.scopus.com/inward/record.url?scp=85088831445&partnerID=8YFLogxK
U2 - 10.1007/s40273-020-00944-0
DO - 10.1007/s40273-020-00944-0
M3 - Article
C2 - 32734572
AN - SCOPUS:85088831445
SN - 1170-7690
VL - 38
SP - 1031
EP - 1042
JO - PharmacoEconomics
JF - PharmacoEconomics
IS - 10
ER -